Hexarelin

Hexarelin, also known as examorelin, is a synthetic six-residue growth hormone secretagogue with an unusually varied research record. Human studies established GH stimulation and showed that responsiveness can diminish during prolonged exposure. Separate cardiac experiments measured short-term changes in heart pumping, including responses in some people with severe GH deficiency, suggesting effects beyond the rise in circulating GH. The findings were not uniform: an acute dilated-cardiomyopathy comparison was negative. Hexarelin is therefore best understood through its individual endocrine and cardiovascular experiments, each of which asks a specific physiological question.

Overview

Hexarelin’s sequence is His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2. The methylated tryptophan building block distinguishes it from GHRP-6, while the amidated end and D-amino acids are shared structural features of this secretagogue family. The sequence is explicitly identified in the childhood-response paper. Klinger et al.

Molecular profile

Peptide core: Hexarelin / examorelin; six residues Source
Sequence, amidated peptide: His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 Source
Distinguishing building block: D-2-methyl-tryptophan at position 2 Source

Forms and derivatives

Examorelin

An alternative name for the hexarelin peptide, used for identity rather than a separate intervention.

Hexarelin photoaffinity derivatives

Modified laboratory probes used to identify and localize CD36 binding. Probe-based target evidence remains labeled to its experimental material.

Its best-known endocrine target is the ghrelin receptor pathway. Binding experiments also identified CD36, a protein involved in uptake and signaling for several lipid-related ligands, as a separate hexarelin target. That second line of research helps explain the cardiovascular interest without making every effect in a heart preparation equivalent to clinical protection.

Uses and research areas

The hormone programme studied acute GH responses, downstream IGF-I and growth velocity in short children, as well as responsiveness over days to months in older adults. These studies make duration especially important: retained responsiveness after a brief experiment can coexist with attenuation during longer exposure.

The cardiovascular programme examined left ventricular ejection fraction, cardiac output, pressure and related measurements in healthy volunteers, people with GH deficiency, patients with dilated cardiomyopathy and men undergoing bypass surgery. Ejection fraction is the percentage of ventricular blood expelled during a beat. It is a useful pumping measurement, while clinical heart-failure benefit additionally involves symptoms, exercise capacity, hospitalization and survival. Bisi et al., Broglio et al., 2001, Broglio et al., 2002

Mechanism of action

Hexarelin stimulates GH through the growth hormone secretagogue system associated with GHS-R1a. The pituitary response is influenced by hypothalamic input, hormone feedback and the condition of GH-releasing cells. GH then acts on peripheral tissues and helps regulate IGF-I production. Studies of repeated responsiveness probe this system over time, with attenuation describing a smaller measured response to a subsequent challenge.

The cardiac findings encouraged investigators to test additional binding sites. Bodart and colleagues used a photoactivatable hexarelin derivative to identify CD36 in rat cardiac membranes. Hexarelin increased coronary perfusion pressure in isolated perfused hearts; the effect was absent in CD36-null mouse hearts and in a rat strain genetically deficient in CD36. The observed direction was a coronary vasoconstrictive response. This experiment is particularly important when reading generalized descriptions of “cardioprotection.”

Demers and colleagues subsequently localized the hexarelin-binding region on CD36 through photoaffinity cross-linking and protein-fragment analysis. That work supports a molecular interaction and overlap with a region involved in oxidized-lipoprotein binding. It does not prove that CD36 alone explains the response in every human cardiac experiment, nor that engaging the protein yields a uniform benefit across vascular disease states.

Pharmacokinetics

The clinical papers reviewed here include intravenous, subcutaneous, intranasal and oral preparations, but their principal serial measurements were GH or downstream hormones. A GH peak or the duration of an ejection-fraction change describes a physiological response. Those time courses do not identify intact hexarelin’s plasma elimination half-life.

No numerical exposure curve is supplied because a route-, analyte- and population-specific primary half-life was not established in this review. Keeping the endocrine time courses in their original units and settings preserves useful temporal evidence without converting it into peptide pharmacokinetics.

Research findings

Short exposure and longer attenuation answer different questions

Ghigo and colleagues conducted two short studies: eight days of intranasal exposure in seven older adults and fifteen days of oral exposure in seven older women. GH responsiveness was maintained in both. IGF-I did not significantly change in the intranasal study and rose modestly in the oral study. Prolactin and cortisol were unchanged under these conditions, with no side effects reported. Participant overlap between the two studies is not established by the abstract.

The longer Rahim and Shalet study followed twelve healthy older adults during sixteen weeks of subcutaneous exposure. Mean integrated GH response declined from 19.1 ± 2.4 at baseline to 10.5 ± 1.8 micrograms/L/hour at week sixteen, reported as mean ± SEM. Four weeks after withdrawal it was 19.4 ± 3.7, significantly higher than at week sixteen and statistically comparable to baseline. This demonstrates partial, reversible attenuation in that sample. The short and long studies differ in route, duration and participants, explaining why their conclusions should remain separate.

Childhood growth and challenge-test responses

Klinger and colleagues followed seven constitutionally short prepubertal children receiving intranasal hexarelin for six to ten months. Acute GH responses to intranasal and intravenous challenge tests diminished, while growth velocity increased from 5.3 ± 0.9 to 7.4 ± 1.6 cm/year, reported as mean ± SD. Responses partly recovered after treatment stopped. The study shows that challenge-test responsiveness and growth velocity did not move together. With no randomized comparison group, it cannot isolate the treatment effect from growth variation or establish final adult height.

Acute cardiac experiments and the negative disease comparison

In the 1999 study, seven male volunteers underwent intravenous hexarelin and recombinant GH comparisons, with cardiac performance measured by radionuclide angiocardiography. Circulating GH exposure was similar across the two conditions. Hexarelin transiently increased ejection fraction, whereas recombinant GH did not; cortisol increased only after hexarelin. The differential cardiac response supports a mechanism extending beyond the measured GH rise.

The 2001 report examined seven healthy adults, seven patients with severe GH deficiency and twelve with severe dilated cardiomyopathy, following measurements for sixty minutes after intravenous hexarelin. Ejection fraction increased in the healthy and GH-deficient groups and did not significantly increase in dilated cardiomyopathy. GH rose in healthy and cardiomyopathy participants, and remained unresponsive in the GH-deficient group. These results separate GH secretion from the cardiac measurement and preserve a consequential negative finding. Possible cohort overlap with the earlier cardiac publication remains unresolved, so the papers are not counted as independent totals of treated people.

The bypass-surgery experiment compared hexarelin with GHRH, recombinant GH and placebo in twenty-four men under general anesthesia. Intraoperative echocardiography and catheter measurements showed increased ejection fraction, cardiac index and cardiac output after hexarelin, along with increased mean arterial pressure and reduced wedge pressure. Other comparators did not show those changes. The measurements extended to ninety minutes and supplied acute hemodynamic evidence; postoperative recovery and survival were outside the demonstrated result.

Safety and tolerability

Hexarelin has no FDA-approved therapeutic indication. Its hormone and cardiovascular activity create several distinct safety questions: GH/IGF exposure over time, accompanying cortisol or prolactin responses, changes in blood pressure and effects within diseased vessels. Acute human experiments and small longitudinal endocrine studies do not resolve uncommon or delayed events.

The early volunteer cardiac comparison observed a cortisol rise, while the shorter oral and intranasal studies found unchanged cortisol and prolactin. Those observations reflect different preparations and exposure settings. The hormone response therefore varied across the tested preparations and exposure settings.

The bypass study’s arterial-pressure increase and the CD36-dependent perfused-heart vasoconstriction are also relevant. They do not quantify a patient’s risk of a cardiovascular event, but they give concrete reasons to assess vascular physiology alongside potentially favorable pumping measurements. Product purity, aggregation, route and formulation introduce further uncertainties for preparations that differ from monitored trial materials.

What the research means

Hexarelin has demonstrated a powerful endocrine stimulus and several acute cardiovascular responses. Its longer hormone studies show that biological responsiveness changes with time. The childhood experiment adds another useful distinction: a smaller challenge-test response can coexist with a higher observed growth velocity.

The cardiac programme supports continued mechanistic interest, particularly because some responses occurred without an accompanying GH rise. Clinical benefit remains indication specific. The negative dilated-cardiomyopathy comparison and the perfused-heart vasoconstrictive finding prevent a single “heart health” description from representing the evidence faithfully.

FAQs

Does responsiveness diminish with prolonged hexarelin exposure?

A sixteen-week study in twelve healthy older adults recorded a partial decline in integrated GH response, with recovery after withdrawal. Shorter oral and intranasal studies maintained responsiveness over days. Their routes, participants and durations differ, so each result should retain its experimental context. Rahim and Shalet

Did the cardiac experiments establish treatment for heart failure?

They measured acute pumping and pressure responses. Some groups showed greater ejection fraction, while the dilated-cardiomyopathy comparison did not. Symptom relief, exercise capacity, hospitalization and survival were not demonstrated by those acute measurements. Broglio et al.

What does CD36 binding add to the interpretation?

CD36 is a second experimentally identified binding target, in addition to the ghrelin-receptor pathway involved in GH release. In isolated hearts supplied with fluid, hexarelin increased the pressure needed to drive flow through coronary vessels, consistent with vessel narrowing. The response disappeared in hearts lacking CD36. This finding helps explain why a change in cardiac biology cannot automatically be described as protection. Bodart et al.

Can a smaller GH challenge response coexist with faster observed growth?

That pattern appeared in the small uncontrolled childhood experiment. Growth velocity rose while acute challenge responses fell. The paired observations show that a challenge response is only one endocrine measurement; comparative growth efficacy and final adult height remain separate questions. Klinger et al.

Ipamorelin, GHRP-2 and GHRP-6 offer related ghrelin-receptor studies with different selectivity, appetite, sleep and exposure findings. Sermorelin provides the GHRH-pathway comparison used to understand how a secretagogue fits within the broader GH system.

References

Bisi G, Podio V, Valetto MR, Broglio F, Bertuccio G, Del Rio G, Arvat E, Boghen MF, Deghenghi R, Muccioli G, Ong H, Ghigo E. Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans. Journal of endocrinological investigation. 1999;22(4):266–272. DOI: 10.1007/BF03343555.
Seven volunteers underwent acute hexarelin/recombinant-GH comparisons with radionuclide cardiac imaging.
Broglio F, Benso A, Valetto MR, Gottero C, Quaranta L, Podio V, Arvat E, Bobbio M, Bisi G, Ghigo E. Growth hormone-independent cardiotropic activities of growth hormone-releasing peptides in normal subjects, in patients with growth hormone deficiency, and in patients with idiopathic or ischemic dilated cardiomyopathy. Endocrine. 2001;14(1):105–108. DOI: 10.1385/ENDO:14:1:105.
The three clinical groups included a negative ejection-fraction comparison in dilated cardiomyopathy.
Broglio F, Guarracino F, Benso A, Gottero C, Prodam F, Granata R, Avogadri E, Muccioli G, Deghenghi R, Ghigo E. Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery. European journal of pharmacology. 2002;448(2-3):193–200. DOI: 10.1016/s0014-2999(02)01934-9.
Intraoperative echocardiography and catheters measured pumping and pressure changes against active and placebo comparators.
Rahim A, Shalet SM. Does desensitization to hexarelin occur? Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 1998;8 Suppl B:141–143. DOI: 10.1016/s1096-6374(98)80039-7.
A sixteen-week endocrine study found partial attenuation and post-withdrawal recovery.
Klinger B, Silbergeld A, Deghenghi R, Frenkel J, Laron Z. Desensitization from long-term intranasal treatment with hexarelin does not interfere with the biological effects of this growth hormone-releasing peptide in short children. European journal of endocrinology. 1996;134(6):716–719. DOI: 10.1530/eje.0.1340716.
The childhood experiment records higher observed growth velocity alongside smaller acute challenge responses.
Ghigo E, Arvat E, Gianotti L, Grottoli S, Rizzi G, Ceda GP, Boghen MF, Deghenghi R, Camanni F. Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging. European journal of endocrinology. 1996;135(4):407–412. DOI: 10.1530/eje.0.1350407.
Two short older-adult studies retained GH responsiveness and found differing IGF-I responses by studied setting.
Bodart V, Febbraio M, Demers A, McNicoll N, Pohankova P, Perreault A, Sejlitz T, Escher E, Silverstein RL, Lamontagne D, Ong H. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circulation Research. 2002;90(8):844–849. DOI: 10.1161/01.RES.0000016164.02525.B4.
A labeled derivative identified CD36; perfused-heart pressure responses depended on CD36 expression.
Demers A, McNicoll N, Febbraio M, Servant M, Marleau S, Silverstein R, Ong H. Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study. Biochemical Journal. 2004;382(Pt 2):417–424. DOI: 10.1042/BJ20040036.
Photoaffinity and protein-fragment analysis localized a hexarelin-binding region on CD36.

Glossary

Ejection fraction: The percentage of ventricular blood expelled during one heartbeat.
Cardiac output: The volume of blood the heart pumps per unit of time.
Cardiac index: Cardiac output adjusted for body surface area.
Wedge pressure: A catheter-derived pressure used to estimate pressure associated with the left side of the heart.
CD36: A cell-surface protein involved in uptake and signaling for several lipid-related ligands.
Photoaffinity labeling: A method using a light-activated probe to identify a molecule’s binding partner.
Desensitization: A reduced biological response after prior or continued exposure.
IGF-I: Insulin-like growth factor I, a downstream mediator influenced by GH and metabolic state.